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Abstract
Background: In aging populations, multimorbidity causes a disease burden of growing importance and cost.
However, estimates of the prevalence of multimorbidity (prevMM) vary widely across studies, impeding valid
comparisons and interpretation of differences. With this study we pursued two research objectives: (1) to identify a
set of study design and demographic factors related to prevMM, and (2) based on (1), to formulate design
recommendations for future studies with improved comparability of prevalence estimates.
Methods: Study data were obtained through systematic review of the literature. UsingPubMed/MEDLINE, Embase,
CINAHL, Web of Science, BIOSIS, and Google Scholar, we looked for articles with the terms “multimorbidity,”
“comorbidity,” “polymorbidity,” and variations of these published in English or German in the years 1990 to 2011.
We selected quantitative studies of the prevalence of multimorbidity (two or more chronic medical conditions) with
a minimum sample size of 50 and a study population with a majority of Caucasians. Our database consisted of
prevalence estimates in 108 age groups taken from 45 studies. To assess the effects of study design variables, we
used meta regression models.
Results: In 58% of the studies, there was only one age group, i.e., no stratification by age. The number of persons
per age group ranged from 136 to 5.6 million. Our analyses identified the following variables as highly significant:
“mean age,” “number of age groups”, and “data reporting quality” (all p < 0.0001). “Setting,” “disease classification,”
and “number of diseases in the classification” were significant (0.01 < p ≤ 0.03), and “data collection period” and
“data source” were non-significant. A separate analysis showed that prevMM was significantly higher in women
than men (sign test, p = 0.0015).
Conclusions: Comparable prevalence estimates are urgently needed for realistic description of the magnitude of
the problem of multimorbidity. Based on the results of our analyses of variables affecting prevMM, we make some
design recommendations. Our suggestions were guided by a pragmatic approach and aimed at facilitating the
implementation of a uniform methodology. This should aid progress towards a more uniform operationalization of
multimorbidity.
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Background
Multimorbidity is a global health challenge of increas-
ing importance. The prevalence of multimorbidity
(prevMM) is a central element in assessing the bur-
den of disease in aging populations. Epidemiological
studies of multimorbidity, most commonly defined as
the co-occurrence of two or more chronic medical
conditions (P2+), have been published for about
20 years now [1, 2]. Still, prevMM in most of these
studies has only limited comparability due to the dif-
ferent study designs and definitions of multimorbidity
used.
There are many aspects of the study design that
can affect the comparability of prevalence estimates,
such as the setting (general population, primary care,
hospital, nursing home), the data source and collec-
tion (patient self-reports /interviews, medical reports,
administrative data), the definition of prevMM, and
the classification of diseases included. Any of these
choices may influence prevalence estimates and thus
affect comparisons between different populations at
the same time (regional variations) or at different
time points (trend estimates). In addition, demo-
graphic and socioeconomic factors are known deter-
minants of multimorbidity [3, 4], especially age and
gender [5, 6]. Nevertheless, estimates of prevMM vary
widely across studies, and this impedes valid compari-
sons and the interpretation of differences between
populations and subpopulations.
Reliable data on the prevalence of multimorbidity
are urgently needed to inform medical and public
health planning and for assessing the effects of med-
ical and public health interventions. In recognition of
these difficulties, the demand for a standardized oper-
ationalization of multimorbidity has been voiced re-
cently [5, 7–10]. Among others, Fortin and colleagues
have worked towards a more uniform definition and
methodology [7, 11].
This study aims to make recommendations for a
standard format in future studies for operationalizing
predictors of prevMM. Our approach is empirical, as we
analyzed data from our systematic review, relating P2+
simultaneously with the determinants mentioned above
using meta analytic methods [12].
Our overall aim was to investigate which study de-
sign variables affect the measured prevalence of mul-
timorbidity (P2+). These variables should be reported
and possibly standardized in future studies. We there-
fore pursued two research objectives: (1) to identify a
set of study design variables and demographic predic-
tors of the prevalence of two or more chronic condi-
tions, and (2) on the basis of (1), to make design
recommendations for future studies of P2+ for opti-
mal comparability.
Methods
Data collection
Data for this study were obtained through a systematic
review of the literature. We screened for relevant articles
published in English or German from January 1990 to
December 2011 using PubMed/MEDLINE and Embase
databases, CINAHL, the Web of Science and BIOSIS da-
tabases, and Google Scholar. For each database, search
strategies with the terms multimorbidity or comorbidity
or polymorbidity and variations of these (e.g., “multi-
morbidity”) were used. We chose a lower boundary to
focus on studies dealing with van de Akker’s concept of
multimorbidity [13] and because publications on multi-
morbidity were rare before 2000 [14].
The literature search was completed by screening the
reference list of included articles. Details regarding the
search strategy and the criteria defined for evaluation
were described elsewhere [12]. Figure 1 shows the flow
diagram of the evaluation process. We included only ori-
ginal studies addressing multimorbidity (two or more
chronic medical conditions and no index disease or spe-
cific disease of interest) with a minimum sample size of
50 and – for homogeneity reasons – a study population
with a majority of Caucasians.
The methods section of the studies included had to
meet standards in research as in the STROBE state-
ment for good reporting of observational studies [15];
in particular, the chronic conditions selected and the
prevalence estimates had to be identifiable. Studies
were also included when explicit prevalence estimates
were missing but could be calculated from the infor-
mation provided in the articles. The sample size of
the study population as well as the setting had to be
reported.
In this way, we compiled a database encompassing 52
studies. If the database of two studies strongly over-
lapped (in numbers and time frame), only the study
deemed the more reliable was included in the analysis.
For the present analysis, 45 studies allowing the estima-
tion of P2+ remained. Key study characteristics are pre-
sented in Additional file 1. In total, 108 prevalence
estimates were extracted from the 45 studies, one for
each age group in each study. In these 108 age groups,
gender was not assessed separately. Studies contributed
between one and six age groups each.
Only seven studies presented prevalence estimates
separately for men and women, resulting in 21 pairs
(one for each sex) of age groups, (e.g., men aged 18–44,
women aged 18–44). These data were used to investigate
the gender effect. Age groups were the primary units of
analysis. Mean age of an age group, if not available in
the original article, was derived from age-specific popu-
lation counts for the respective study year(s) in the Hu-
man Mortality Database [16].
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Classification of variables
Apart from the response variable P2+, the following var-
iables were collected: origin/country of study population,
setting (general population, primary care, hospital or
nursing home, health insurance), data source (self-re-
port, medical records, self-report combined with medical
records, administrative data), length of data collection
period, total sample size, number of age groups, range
and mean age of each age group, number of individuals
per age group, data reporting quality (data from original
paper, calculated from numbers given in the paper, P2+
estimated from P3+ [12], or extracted from graph), and
number of items in the classification of chronic condi-
tions used.
We used two variables to characterize the disease
classification: (1) a variable “disease classification,”
characterizing the principle underlying the list of dis-
eases considered, with (a) diseases from an inter-
nationally standardized disease classification coding
system (e.g., ICD-10, ICPC-2) or (b) diseases de-
scribed informally by the name of a disease (e.g.,
heart disease, diabetes), and (2) a variable “number of
diseases in the classification,” counting the number of
items in the classification used.
All 45 articles fulfilled at least 12 of the 22 possible
quality criteria on the STROBE checklist (see Additional
file 1) [15]. We applied the PRISMA checklist as far as
possible (as described elsewhere [12]).
Statistical analysis
Tables, percentages, medians, means and SD, and
minima and maxima were used for descriptive analyses.
Sign test as well as clustered regression (clusters = stud-
ies) were used for paired comparisons to investigate the
gender effect. To assess the effects of the variables re-
ported in Tables 1, 2 and 3, weighted regression models
with a random effect at the level of age groups were
used for logit P2+. These models account for unex-
plained variability between age groups, thus preventing
spurious precision. We did several analyses, beginning
with a detailed model similar to the model in Table 4
but with “number of diseases in the classification” with
22 levels and then successively combining variable cat-
egories with comparable effect to obtain a stable, not
over-parametrized model. Models were assessed and var-
iables were tested for significance using F-Tests; p < 0.05
was considered significant and p < 0.01 as highly signifi-
cant. Graphs were used to visualize the effect of certain
variables and to compare observed and fitted prevalence.
Results
Characteristics of the studies
Table 1 presents statistical information on the studies in-
cluded in the data analysis. Our data set covered a wide
variety of studies and included 17 countries and four dif-
ferent settings.
Fig. 1 PRISMA flow diagram
Holzer et al. Population Health Metrics  (2017) 15:9 Page 3 of 9
The number of single diseases listed ranged from five
up to more than 300 items (single or grouped diseases),
with a median number of 16 diseases. In each of the
reviewed papers, an individual list of diseases/conditions
was used for assessing multimorbidity (= two or more
concurrent chronic conditions, P2+). In two out of three
studies, the classification scheme was based on specific
disease names/disease groups, whereas in the remaining
studies the scheme was based on codes from an inter-
national classification of diseases system such as ICD-10
or ICPC-2. The number of participants per study ranged
from 301 in the smallest study to 5.6 million in the lar-
gest. In 58% of the studies there was only one rather
wide age group; other studies had up to six age groups.
Descriptive statistics
Table 2 and 3 provide statistical information on the 108
age groups, the basic units of observation in this study.
Salient points were: first, the large variability of the
number of persons per age group, from 136 to 5.6 mil-
lion (variation by a factor exceeding 40,000), and second,
the wide variability of prevalence estimates found (e.g.,
from 0.3 to 98.7% for P2+).
Eighty-eight of 108 estimates of P2+ were either taken
directly from the study paper or derived from numbers
in the paper; six more were computed from separate
estimates for men and women. Eight values of P2+ were
extracted from graphs and another six calculated from
the corresponding P3+ prevalence [12].
The gender effect was investigated by looking at the
21 pairs of P2 + -values available from seven studies pre-
senting sex-specific figures for the same age group.
Paired comparison showed that under similar circum-
stances (same age group, same study), women had a
3.0% higher prevalence P2+ than men (95% confidence
interval [CI]: 0.84%, 5.2%, clustered regression). Women
showed higher P2+ than men in 18 of the 21 prevalence
pairs (p = 0.0015, sign test).
Meta regression models
All other variables, including age, were investigated
using meta regression models. A model incorporating all
Table 1 Characteristics of studies used in the data analysis (N = 45)
Topic Description Number
Study
characteristics
Studies contributing age groups 45
Studies comprising several
distinct substudiesa
3
Countries represented 17
Setting General population 21
Primary care practice 12
Hospital/nursing home 3
Health insurance 8
Several settings
(and different data sets)b
1
Disease
classification
Name of diseases/disease
groups only
30
Diseases based on international
classification systems
15
No. of diseases in
the classification
Range of diseases under study 5 to over 300
Median 16
Data collection
period
Up to one year 25
One year or more 19
Several periodsc 1
No. of study
participants
Range of persons under study 301 to 5.6 million
Median 6864
No. of age
groups
1 26
2 to 3 9
4 to 6 10
a[19, 39, 40]
b[19]
c[39]
Table 2 Descriptive statistics for the age groups included
Items N Mean SD Min Max
Limits
Lower limit of age group given 104 50.7 24.5 0 85
Lower limit of age group imputed 4 15 n.a. n.a. n.a.
Upper limit of age group given 70 66.6 19.9 17 99
Upper limit of age group imputed 38 90 n.a. n.a. n.a.
Mean agea 108 60.3 20 9 89.3
Size
No. of persons in age group 108 116,940 585,066 136 5,585,931
Prevalence
P2+ (2 or more chronic conditions) 102 46.6% 24.4 0.3% 98.7%
P3+ (3 or more chronic conditions) 76 28.7% 22.0 0.0% 95.7%
aWhen mean age was not indicated, it was derived from the Human Mortality Database [16]
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variables had a good fit (adjusted R2 = 90.0%, residual
unexplained variance = 0.197, F (45, 62) = 20.17, p <
0.00005) but showed clear signs of overfitting. Omitting
insignificant variables and lumping together adjacent
variables categories that showed almost identical effects,
there resulted a model with 20 parameters that provided
a reasonable fit (adjusted R2 = 70.6%, residual variance =
0.5812, F(20, 87) = 12.61, p < 0.00005) and no evidence
of overfitting. In this model, the following three determi-
nants proved to be highly significant: “mean age” (t =
12.16, p < 0.0005), with a change in logit P2+ of 0.052
per year; “number of age groups” in the study (F(5, 87)
= 9.82, p < 0.00005), and “data reporting quality” (F(2,
87) = 10.78, p = 0.0001). In addition, “disease classifica-
tion” (F(2, 87) = 4.87, p = 0.01), “number of diseases in
the classification” (F(3, 87) = 3.18, p = 0.03), and “setting”
(F(3, 87) = 3.04, p = 0.03) proved to be significant deter-
minants. On the other hand, the items “data collection
period” and “data source” were not significant, with p
values of 0.12 and 0.16, respectively. Table 4 presents the
parameter estimates of this model.
Figure 2 presents a scatter plot of observed and
predicted prevalence estimates. Observed prevalence
estimates cover the range from 0.3 to 98.7%, fitted
estimates from 0.5 to 90.4%; the upper end was not
fitted as well as the lower one. Differences ranged from
−27 to 39%, with 50% between −10.5 and +8.8%, the
mean deviation being 10.2%.
Figure 3 shows the relative effect on logit P2+ of chan-
ging from a study with one age group to more than one
age group. The maximum of P2+ is reached at four age
groups. At two age groups, there is a dip in the effect.
However, there were only two studies with two age
groups.
Figure 4 shows the relative effect on logit P2+ of going
from a study with fewer than 10 diseases in the list used
to studies with disease lists with higher numbers. The
maximal prevalence P2+ is reached with lists of from 25
to 74 diseases, with a decrease with higher numbers of
diseases in the classification.
Some of our findings may appear counter-intuitive at
first sight, such as the finding that setting is not of high
significance. This result states that with all other variables
Table 3 Qualitative statistics for the age groups (N = 108)
Source of information N %
Source for P2+ (prevalence of 2 or more chronic conditions)
Taken from paper 39 36.1%
Calculated from paper 55 50.9%
Extracted from graph 8 7.4%
Estimated using P3 + a 6 5.6%
Source of age limits
Both limits from paper 66 61.1%
Lower limit imputed 4 3.7%
Upper limit imputed 38 35.2%
Both limits imputed 0 0%
aUsing Holzer et al.’s [12] method
Table 4 Variables and effect estimates from the model
Characteristics Categories Effect estimate 95% CI
Mean age Years 0.052 0.044, 0.061
Number of age
groups
1 0 –
2 −2.7 −3.69, −1.71
3 0.391 −0.14, 0.92
4 0.474 −0.10, 1.05
5 0.102 −0.47, 0.67
6 0.001 −0.87, 0.87
Disease
classification
Names of specific
disease/disease groups
0 –
Diseases based on
ICD-10 or ICD-9 codes
1.26 0.039, 2.49
Diseases based on
ICPC-2 or CIRS
−0.789 −1.64, 0.067
No. of diseases
in the
classification
5–9 0 -
10–24 0.516 0.0017, 1.03
25–74 1.22 0.43, 2.01
≥75 0.806 −0.47, 2.08
Setting General population 0 –
Primary care practice 0.015 −0.70, 0.73
Hospital/nursing
home
1.41 0.39, 2.44
Health insurance 1.05 −0.66, 2.76
Data source Self-report 0 –
Medical record −0.863 −1.71, −0.019
Self-report + medical
record
−0.75 −1.43, −0.071
Administrative data −0.497 −2.39, 1.39
Data collection
period
Up to one year 0 –
One year or more −0.349 −0.79, 0.09
Data reporting
quality
P2+ given in paper 0 –
P2+ calculated
from paper
−0.4 −0.94, 0.14
P2+ read from
graph in paper
−1.76 −2.52, −0.99
Constant −3.305 −4.01, −2.60
Legend: Random effects model with response: logit P2+, sampling weights inverse
to binomial variance of logit P2+; average sampling weight: 0.0182.
N= 108; adjusted R2 = 70.6%; residual variance τ2 = 0.5812; overall
F(20,87) = 12.61; p < 0.00005
Categories with “Effect estimate” = 0 are reference categories. Gender analyses
were done using a different data set (see text). Mean age: Effect estimate
gives the change in logit P2+ when changing mean age by one year. Other
variables: Effect estimate quantifies the effect on logit P2+ of going from the
reference category to the category of interest – e.g., going from one age group
to two changes logit P2+ by −2.70, when keeping all other variables fixed
(also see Discussion)
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in the model, the additional contribution of the variable
“setting” to an optimal fit is barely significant. Comparing
the settings “primary care practice” and “hospital,” for ex-
ample, our analysis does not state that there is no differ-
ence between those two settings in the level of P2+.
However, adjusted for age, number of age groups in the
study, data reporting quality, and disease classification
used, the remaining differences in P2+ between the
settings “primary care practice” and “hospital” almost
disappeared. In the 45 studies available for analysis, the
variables “data source” and “setting” were highly inter-
dependent, e.g., health insurance databases contain ad-
ministrative data only (data not shown).
Discussion
Using data from a systematic review of 45 articles from
17 countries, we analyzed various variables regarding
their impact on the prevalence estimates of multimor-
bidity, defined as the co-occurrence of two or more
chronic conditions. To our knowledge this is the first
study simultaneously considering population-related and
design-related variables that influence P2+. As is well-
known, age is an important determinant of the preva-
lence of multimorbidity [3, 5, 17]. So is gender, although
that is less well-established [18]. We quantified the preva-
lence difference between men and women, with women
showing on average a significant nearly 3% higher preva-
lence of P2+. This result agrees with women reporting
higher prevalence of long lasting health problems (e.g.,
Swiss Statistical Office: https://www.bfs.admin.ch/bfs/
de/home/statistiken/gesundheit/gesundheitszustand.html
[18]). Less well known is the influence of study vari-
ables on the prevalence of multimorbidity such as the
“number of age groups” (highly significant), “setting”
(significant), and “number of diseases in the classifica-
tion” used (significant) [5, 19, 20].
Before discussing these results, we would like to
emphasize a few limitations in order to set the context
of the validity of the findings of our study.
First, as in any systematic review, we cannot exclude
bias in the search strategy used or resulting methodo-
logical bias due to the heterogeneity of the studies
analyzed. A certain reassurance regarding these bias
problems lies in the fact that our review is based on
widely varying studies with differences in study design,
instruments, scope, sample selection, assessed variables,
and the language of the included studies, etc. Second,
our basic units of observation were age groups, which
entails several problems, such as the use of aggregated
data. Thus, for example on the individual level, the age
effect might be rather more pronounced than our result
suggests. Third, we found considerable unexplained
variation between studies, necessitating the use of ran-
dom effect models. The correspondence of observed and
fitted prevalences leaves room for considerable improve-
ment. However, we believe that substantial improvement
Fig. 2 Observed versus predicted percentage of multimorbidity P2+
in a scatter plot
Fig. 3 Effect of the number of age groups used in a study on
multimorbidity P2+. Category “one age group” is the reference
Fig. 4 Effect of the number of diseases used in a study on
multimorbidity P2+. Category “fewer than 10 diseases on list” is
the reference
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in fit can only be realized by improving the quality of
studies of P2+. Thus, it might be useful to report study-
specific regressions of prevalence of multimorbidity on
age and gender in the future. Fourth, as in any multivari-
able analysis, interactions between the various variables
are to be expected, which, with only 108 observations,
we were unable to model. Therefore, our analysis could
only provide a rough but we believe nevertheless useful
description of the current situation regarding the influ-
ence of study design and demographic variables on
prevMM. Finally, it has to be mentioned that, due to the
scarcity of adequate data, we did not investigate the
impact of socioeconomic status [4], the prevalence of
disease patterns [21, 22], or the simultaneous use of two
or more data sources [22, 23].
Despite these limitations, we believe that this paper
contributes towards improving the design of multimor-
bidity studies.
Significant age and gender effects in multimorbidity
have been reported in several studies [3–5, 17, 24–29].
In our study, age effect was substantial, too: average
prevalence at mean ages 55 to 64 was 44.9%, whereas at
mean ages 65 to 74, it was 51.3%, which is a relative in-
crease of 14.2% within 10 years of age. Compared to this,
the difference between women and men amounted to
only 3.0% on average [18].
In our multivariable analyses, the “number of age
groups included in the study” also had a highly signifi-
cant effect on prevMM. The effect of number of age
groups on P2+ was clear, but due to an outlier at two
age groups, it is not easy to interpret. Here, further
research may be needed. The implementation of age
groups, in other words stratification by age, would allow
better age adjustment and thus more precise compari-
sons of populations. To our knowledge, the use of age
stratification was explicitly recommended by only one
research group [30], although a priori epidemiological
considerations would suggest it. Moreover, in our sys-
tematic review, 58% of all studies had only one, mostly
wide age group. A few articles mentioned the impact of
the study setting on prevMM [6, 19]. Differences in
prevMM between the general population and primary
care practices were described, the researchers stating
that a health care setting can be expected to show higher
prevalence than a general public setting. Our analysis
showed that “setting” as such had only a marginal influ-
ence on prevMM – that is, differences in prevMM
between settings such as those mentioned above were
largely due to differences in age structure between the
study populations and possibly some study design
variables.
The item “data source” seemed to have no relevant
effect in our analysis. In contrast, other studies found
“data source” (e.g., self-reported data vs. administrative
data) to have a significant influence on prevMM [19, 22,
31]. However, most of those studies did not suggest an
adjustment for other important variables such as age and
number of age groups.
In our analyses, “disease classification” and “number of
diseases in the classification” had a significant effect on
prevMM. Several research groups [5, 8, 32] have de-
scribed the impact of the number of disease categories
and pointed out the need for a consensus on a common
classification of chronic conditions characterizing multi-
morbidity. Suggestions in this direction have been for a
range of single diseases between 11 [33] and 30 [34].
Our results indicated that studies using classifications
with fewer than 25 or more than 75 chronic conditions
tended to yield lower prevalence estimates and thus
confirmed a need to standardize disease classification to
estimate prevMM. In our opinion, this choice should
lead to the highest prevalence. Therefore, an upper limit
is reasonable, because for more than 74 diseases, the
effect of the number of diseases in the list on the fitted
P2+ decreases again.
The “type of disease classification” – another study de-
sign variable not investigated in previous studies – had
highly significant effects on prevMM in our analysis.
This variable can be seen as a quality criterion to indi-
cate whether the single disease entities were classified
according to internationally accepted coding systems
(e.g., ICD-10) or not. To quantify the burden of multi-
morbidity, it seemed sensible to us to suggest choices of
design variables that maximize the resulting prevalence
estimates. Therefore, we propose choosing a list of chronic
conditions that contains from 25 to 75 single conditions.
Other authors have suggested classifications of similar
size, such as the top 20 single diseases evaluated by
Prados-Torres et al. [9] in their systematic review. The
most frequent diseases were hypertension, COPD,
diabetes, malignancy, stroke, dementia, depression, joint
disease, anxiety, congestive heart failure, coronary heart
disease, asthma, cardiac arrhythmia, thyroid disease,
anemia, hearing problems, dyslipidemia, obesity, prostatic
hypertrophy, and osteoporosis. In another systematic re-
view, Sinnige et al. [35] assessed the top 20 diseases almost
identically to Prados-Torres et al. In addition, Tonelli
[34] identified a panel of 30 chronic conditions to be
used in administrative data for which the best identi-
fied algorithm was of high or moderate validity. Alter-
natively, O’Halloran’s definition of chronicity could be
useful as an underlying concept [36], as was applied by a
Spanish and an Australian research group [32, 37].
To characterize multimorbidity, we suggest using the
diseases identified in the studies named above. Such a
core set of diseases and conditions could then be com-
plemented by highly prevalent or critical chronic condi-
tions relevant to the population under study.
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The majority of the studies used in our analysis included
the non-communicable chronic diseases that are highly
prevalent in high income countries. But when looking at
multimorbidity in a more global perspective or in low/
middle income countries, other or additional relevant
global chronic illnesses might have to be considered [38].
In recognition of some of the difficulties mentioned
above, a need has been voiced lately for more uniform
methods to enable solid comparisons between prevMM in
different populations or over time [5, 7–10] and subse-
quently to create a solid database of prevMM. Data of that
kind are urgently needed to inform medical and public
health planning and, in the longer term, for assessing the
effects of medical, public health, or other interventions.
Criteria for a meaningful operationalization of multimor-
bidity, especially for epidemiological research, have been
proposed by various researchers [7, 8, 19, 30]. Recently, an
international research group advocated a method for
validly identifying chronic conditions in administrative
data [34] as a core set for designing observational studies.
According to our second research objective, based on
our empirical evaluation and the considerations above,
we derive recommendations regarding standards for
future studies of the prevalence of multimorbidity. Thus,
to enhance comparability of prevalence estimates, as
well as to facilitate the combining of information from
various studies (national and international), the follow-
ing aspects should be considered in the planning of new
epidemiological studies:
1. An overview of the population under study (gender,
age range, setting, other socioeconomic variables)
and the study design variables (total number of
persons under study data source/data collection
method, period of the data collection, etc.) should
be standard for studies on the prevalence of
multimorbidity.
2. Prevalence estimates should be given stratified by
gender and age group to permit proper adjustment.
3. In the case of small databases or age-related limita-
tions in the study design, stratification into at least
three age groups with definite, pre-chosen upper
and lower limits should be made. Alternatively, 10-
year age groups could be considered, as practiced
routinely by the World Health Organization.
4. The classification of chronic conditions used should
comprise between 25 and 75 items. Both the name
of the disease as well as the respective related code
from an internationally accepted classification
system should be documented.
Conclusions
Our research revealed that at present, prevalence data on
multimorbidity are less reliable than they could be. The
main reasons for this are insufficient standardization and
a lack of adequate control of key variables associated with
the prevalence of multimorbidity. Our suggestions for in-
creasing the comparability of prevalence data in future
studies were guided by a pragmatic empirical approach
and aimed at facilitating the implementation of a uniform
methodology. We expect that we can contribute to pro-
gress towards a more uniform definition of multimorbidity
and its prevalence. Reliable and thus comparable data of
multimorbid populations are urgently needed, not only in
order to identify the magnitude of the problem but also to
measure intervention effects in populations. To achieve
this goal, a consensus on the operationalization of multi-
morbidity and prevalence of multimorbidity has to be
reached. This paper provides an empirical basis for that
consensus.
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